venetoclax + artemisinin

Venetoclax + artemisinin refers to a series of novel chemical conjugates (such as A19, A20, and A21-A23) that link the Bcl-2 inhibitor venetoclax with dihydroartemisinin (DHA), a derivative of artemisinin. These conjugates are designed to overcome resistance in acute myeloid leukemia (AML) by simultaneously inhibiting Bcl-2 and promoting the NOXA-mediated degradation of Mcl-1. Developed by researchers at Shenyang Pharmaceutical University and the Samuel Waxman Institute for Aging and Cancer, these next-generation derivatives utilize optimized linkers, including polyethylene glycol (PEG) units and nitrogen-containing polar groups, to improve water solubility and bioavailability compared to earlier versions. Preclinical studies have demonstrated that these conjugates exhibit potent antileukemic effects, including inhibition of colony formation and significant tumor growth suppression in vivo.

Other names

venetoclax-artemisinin conjugatesvenetoclax-dihydroartemisinin conjugates